The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: Prospects and future directions

Seminars in Oncology

Volumn 29, Issue 5 SUPPL. 15, 2002, Pages 34-39

  Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANGIOGENESIS INHIBITOR; ANTIBODY; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE INHIBITOR; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; RITUXIMAB; SEMAXANIB; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TRASTUZUMAB; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0037010069     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)90018-7     Document Type: Article

References (51)

1. Buyse M, Zeleniuch-Jacquotte A, Chalmers T: Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259:3571-3578, 1988
2. Moertel C, Fleming T, Macdonald J, et al: Levamisole and fluorouracil for adjuvant therapy of resected colorectal carcinoma. N Engl J Med 322:352-358, 1990
3. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
4. de Gramont A, Bosset J-F, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 15:808-815, 1997
5. O'Connell M: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer: A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63:1026-1030, 1989
6. Grothey A, Schmoll H: New chemotherapy approaches in colorectal cancer. Curr Opinion Oncol 13:275-286, 2001
7. Pazdur R, Douillard J, Skillings J, et al: Multicenter phase III study of 5-fluorouracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:264a, 1999 (abstr)
8. Cox J, Pazdur R, Thibault A, et al: A phase III trial of XELODA TM (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:265a, 1999 (abstr)
9. Twelves C, Harper P, Van Cutsam E, et al: A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:203a, 1999 (abstr)
10. Cunningham D, James R: Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur J Cancer 37:826-834, 2001
11. Cocconi G, Cunningham D, Van Cutsem E, et al: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 15:2943-2952, 1998
12. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer: Results of a randomized multicenter North American trial. Proc Am Soc Clin Oncol 16:228a, 1997 (abstr)
13. Cunningham D, Zalcberg J, Rath U, et al: Final results of a randomized trial comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" colorectal cancer study group. Ann Oncol 7:981-985, 1996
14. Schilsky R, Bukowski R, Burris H, et al: A multicenter phase II study of a 5-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol 11:415-420, 2000
15. Mani S, Hochster H, Beck T, et al: Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol 18:2094-2091, 2000
16. Shimada Y, Rougier P, Pitot H: Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 32A:S13-S17, 1996
17. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16:2739-2744, 1998
18. Andre T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35:1343-1347, 1999
19. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
20. deBraud F, Munzone E, Nole F, et al: Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol 21:279-283, 1998
21. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
22. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
23. Grothey A, Deschler B, Kroening H, et al: Bolus 5-fluorouracil (5-FU/Folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC). Result of a phase III study. Proc Am Soc Clin Oncol 20:125a, 2001 (abstr 496)
24. Douillard J, Cunningham D, Roth A, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 355:1041-1047, 2000
25. Saltz L, Cox J, Blanks O, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905-914, 2000
26. Sargent D, Niedzwiecki D, O'Connell M, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001
27. Rothenberg M, Meropol N, Poplin E, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
28. Borner M, Mueller S, Roth A, et al: Phase II study of capecitabine (CAP) + oxaliplatin (OXA) in first line and second line treatment of advanced or metastatic colorectal cancer (ACC). Proc Am Soc Clin Oncol 20:137a, 2001 (abstr 546)
29. Diaz-Rubio E, Evans J, Tabernero J, et al: Phase I study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors. Proc Am Soc Clin Oncol 19:198a, 2000 (abstr 772)
30. Schleucher N, Tewes M, Achterrath W, et al: Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 20:141a, 2001 (abstr 561)
31. Cassata A, Stani S, Alu M, et al: Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 20:144a, 2001 (abstr 573)
32. Douillard J, Seitz J: A phase I study of oral uracil/tegafur (UFT) plus leucovorin combined with oxaliplatin in patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 20:144a, 2001 (abstr 572)
33. Speyer J, Hochster H, Chachoua A, et al: A phase I/II study of eniluracil/5FU plus oxaliplatin (FOX-E) in patients with pre-treated colorectal cancer. Proc Am Soc Clin Oncol 20:144a, 2001 (abstr 574)
34. Adam R, Bismuth H, Castaing D, et al: Repeat hepatectomy for colorectal liver metastases. Ann Surg 225:51-60, 1997
35. Meta-Analysis-Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases in colorectal cancer. J Natl Cancer Inst 88:252-258, 1996
36. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann Surg Oncol 8:347-353, 2001
37. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520, 1996
38. Giacchetti S, Itzhaki M, Gruia G, et al: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and surgery. Ann Oncol 10:663-669, 1999
39. Maindrault F, Louvet C, André T, et al: Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR). Proc Am Soc Clin Oncol 20:146a, 2001 (abstr 581)
40. Maindrault-Goebel F, Louvet C, Carola E, et al: Oxaliplatin reintroduction in patients pretreated with leucovorin (LV), 5-FU and oxaliplatin for metastatic colorectal cancer. A Gercor Study. Proc Am Soc Clin Oncol 19:255a, 2000 (abstr 990)
41. Scheithauer W, Kornek G, Ulrich-Pur H, et al: Irinotecan (CPT-11) plus oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A randomized phase II study. Proc Am Soc Clin Oncol 20:135a, 2001 (abstr 538)
42. Kemeny N, Tong W, DiLauro C, et al: Phase I/II trial of weekly oxaliplatin (OXA) and irinotecan (CPT-11) in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 20:133a, 2001 (abstr 529)
43. Kretzschmar A, Thuss-Patience P, Grothey A, et al: Weekly combination of oxaliplatin (OX) and irinotecan (Iri) in 5-FU resistant metastatic colorectal cancer. Proc Am Soc Clin Oncol 20:136a, 2001 (abstr 540)
44. Van Triest B, Pinedo H, Giaccone G, et al: Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385-391, 2000
45. Park D, Stoehlmacher J, Zhang W, et al: Human thymidylate synthase gene polymorphism determines response to capecitabine chemotherapy in advanced colorectal cancer. Proc Am Soc Clin Oncol 20:129a, 2001 (abstr 514)
46. Hummer A, Kemeny N, Zervoudakis A, et al: Molecular markers affect survival following adjuvant treatment for resected hepatic metastases from colorectal cancer (CRC). Proc Am Soc Clin Oncol 20:130a, 2001 (abstr 516)
47. Hwang J, Sinicrope F, Safran H, et al: A phase II trial of irinotecan and trastuzumab (Herceptin) in patients overexpressing HER-2/neu in metastatic colorectal cancer. Proc Am Soc Clin Oncol 20:142a, 2001 (abstr 565)
48. Punt C, Nagy A, Douillard J, et al: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer. A randomized study. Lancet. Available at http://image.thelancet.com/extras/01art6241web.pdf.
49. Dencausse Y, Hartung G, Sturm J, et al: Prospective randomized study of adjuvant therapy with edrecolomab (Panorex) of stage 11 colon cancer. Proc Am Soc Clin Oncol 20:112b, 2001 (abstr 2198)
50. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMCC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
51. Miller L, Elfring G, Hannah A, et al: Efficay results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients from a phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 20:144a, 2001 (abstr 571)